Bio-Rad acquires Curiosity Diagnostics for $170M

By staff writers

August 3, 2022 -- Bio-Rad Laboratories said Wednesday that it is acquiring Curiosity Diagnostics from Scope Fluidics, a Warsaw, Poland-based developer of molecular diagnostic tests, for up to $170 million.

Bio-Rad said that as part of the acquisition agreement it will pay approximately $100 million in cash and up to $70 million based on future milestones being achieved.

Curiosity Diagnostics, a late-stage, precommercial platform company, is developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market.

"Curiosity's PCR platform ... provides a streamlined workflow as well as rapid turnaround times, and is expected to extend our reach beyond high-complexity labs into near-patient molecular diagnostics labs," Dara Wright, Bio-Rad's EVP and president of its clinical diagnostics group, said in a statement.

Bio-Rad reports Q2 revenue drop, COVID-19 sales decline
Bio-Rad Laboratories on Thursday reported second quarter revenues of $691.1 million, down 3% from $715.9 million in Q2 2021 and short of Wall Street analysts’...
Bio-Rad launches Duet PCR system for researchers
Bio-Rad Laboratories has launched its CFX Duet real-time PCR system to support researchers in developing singleplex and duplex quantitative PCR assays.
Bio-Rad launches new SARS-CoV-2 panels
Bio-Rad Laboratories has launched Bio-Plex immunoglobulin A (IgA) and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens....
Bio-Rad partners with Seegene
Bio-Rad Laboratories announced a partnership with South Korean molecular diagnostics company Seegene to develop and commercialize new diagnostic products...

Copyright © 2022

Last Updated mp 8/3/2022 2:26:03 PM